Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Imagem de Miniatura
Arquivos
art_ROBAK_BortezomibBased_Therapy_for_Newly_Diagnosed_MantleCell_Lymphoma_2015.PDF (441.71 KB)
Citações na Scopus
321
Tipo de produção
article
Data de publicação
2015
Editora
MASSACHUSETTS MEDICAL SOC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
ROBAK, Tadeusz
HUANG, Huiqiang
JIN, Jie
ZHU, Jun
LIU, Ting
SAMOILOVA, Olga
PYLYPENKO, Halyna
VERHOEF, Gregor
SIRITANARATKUL, Noppadol
OSMANOV, Evgenii
Autor de Grupo de pesquisa
LYM-3002 Investigators
Editores
Coordenadores
Organizadores
Citação
NEW ENGLAND JOURNAL OF MEDICINE, v.372, n.10, p.944-953, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. METHODS In this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. RESULTS After a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. CONCLUSIONS VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137.)
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/9259
Referências
  1. [Anonymous], 2014, VELC BORT INJ SUB IN
  2. Barbee MS, 2013, ANN PHARMACOTHER, V47, P1136, DOI 10.1177/1060028013503122
  3. Broyl A, 2010, LANCET ONCOL, V11, P1057, DOI 10.1016/S1470-2045(10)70206-0
  4. Cavaletti G, 2010, LEUKEMIA LYMPHOMA, V51, P1178, DOI 10.3109/10428194.2010.483303
  5. Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
  6. Determann O, 2008, BLOOD, V111, P2385, DOI 10.1182/blood-2007-10-117010
  7. Dreyling M, 2014, ANN ONCOL, V25, P83, DOI 10.1093/annonc/mdu264
  8. Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665
  9. Flinn IW, 2014, BLOOD, V123, P2944, DOI 10.1182/blood-2013-11-531327
  10. Furman RR, 2010, CANCER-AM CANCER SOC, V116, P5432, DOI 10.1002/cncr.25509
  11. Garcia M, 2009, CANCER, V115, P1041, DOI 10.1002/cncr.24141
  12. Goy A, 2009, ANN ONCOL, V20, P520, DOI 10.1093/annonc/mdn656
  13. Goy A, 2010, LEUKEMIA LYMPHOMA, V51, P1269, DOI 10.3109/10428194.2010.483302
  14. Herrmann A, 2009, J CLIN ONCOL, V27, P511, DOI 10.1200/JCO.2008.16.8435
  15. Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466
  16. Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331
  17. Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288
  18. Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871
  19. Kluin-Nelemans HC, 2012, NEW ENGL J MED, V367, P520, DOI 10.1056/NEJMoa1200920
  20. Lenz G, 2005, J CLIN ONCOL, V23, P1984, DOI 10.1200/JCO.2005.08.133
  21. Lonial S, 2008, BRIT J HAEMATOL, V143, P222, DOI 10.1111/j.1365-2141.2008.07321.x
  22. Lonial S, 2005, BLOOD, V106, P3777, DOI 10.1182/blood-2005-03-1173
  23. McKay P, 2012, BRIT J HAEMATOL, V159, P405, DOI 10.1111/bjh.12046
  24. Moreau P, 2011, LANCET ONCOL, V12, P431, DOI 10.1016/S1470-2045(11)70081-X
  25. Mounier N, 2008, ANN ONCOL S4, V19
  26. Murai K, 2014, EUR J HAEMATOL, V93, P290, DOI 10.1111/ejh.12342
  27. National Cancer Institute, COMM TERM CRIT ADV E
  28. National Comprehensive Cancer Network, 2014, NCCN CLIN PRACT GUID
  29. O'Connor OA, 2009, BRIT J HAEMATOL, V145, P34, DOI 10.1111/j.1365-2141.2008.07466.x
  30. Ribrag V, 2009, CANCER, V115, P4540, DOI 10.1002/cncr.24518
  31. Ruan J, 2011, J CLIN ONCOL, V29, P690, DOI 10.1200/JCO.2010.31.1142
  32. Rummel MJ, 2013, LANCET, V381, P1184
  33. Shi DS, 2014, J CLIN INVEST, V124, P3757, DOI [10.1172/JCI75247, 10.1172/JC175247]
  34. Tiemann M, 2005, BRIT J HAEMATOL, V131, P29, DOI 10.1111/j.1365-2141.2005.05716.x
  35. Vose Julie M, 2013, Am J Hematol, V88, P1082, DOI 10.1002/ajh.23615
  36. Williams ME, 2013, HEMATOL-AM SOC HEMAT, P568

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03